NNature Communications6d ago

Anti-PD-1 plus nab-paclitaxel and bevacizumab for second-line treatment of cancer of unknown primary (Fudan CUP-002): a phase II trial

Xiaowei Zhang·Zhiguo Luo·Midie Xu·Yanjing Guo·Qifeng Wang·Yanli Wang·Liangping Zhou·Silong Hu·Qinghua Xu·Xichun Hu·Xin Liu·Ting Zhao

Read at Nature Communications

Tags

Cancer Diagnosis and TreatmentOncology